Reaching Others University at Buffalo - The State University of New York
Skip to Content
Richard                        Quigg Jr.

Richard J. Quigg Jr. MD

Department of Medicine

Arthur M. Morris Professor and Chief, Division of Nephrology

Specialty/Research Focus


top-left cornertop-right corner
Professional Summary:

My work over the past several decades has concentrated on understanding mechanisms of kidney disease. We have studied animal models of systemic lupus erythematosus, diabetic nephropathy, glomerulonephritis, obstructive nephropathy, and acute renal failure. In addition to modeling disease in animals, we also have performed clinical studies both for promising new therapies and examining gene profiles from renal tissue.
To answer questions that arise in the course of our research, our work has spanned a number of disciplines and utilizes state-of-the-art approaches. For example, our expanding work in genomics and computational biology led to my founding the Bioinformatics and Computational Biology Core Facility (BCBCF) and the Functional Genomics Facility (FGF) during my time at the University of Chicago.
In addition to my basic science work, I am also clinically active. My practice is geared towards the diseases I study in animals, including through focused outpatient clinics with a relatively large cohort of patients with immunologically-mediated renal diseases. Overall, my clinical and basic science work is interrelated and mutually informative.

Education and Training:
  • Fellowship, Nephrology, Boston University Medical Center (1988)
  • Residency, Internal Medicine, University Hospital, SUNY-Stony Brook (1984)
  • MD, Internal Medicine, Boston University School of Medicine (1981)
  • BA, Medical Sciences, Mathematics Minor, Boston University, Summa cum laude (1981)
  • Professor of Medicine, University at Buffalo (2013-present)
  • Professor of Medicine, Emeritus, University of Chicago, The University of Chicago (2013-present)
  • Adjunct Professor of Oncology, Roswell Park Cancer Institute (2013-present)
  • Chief, Division of Nephrology, University at Buffalo (2013-present)
  • Professor of Biomedical Informatics, University at Buffalo (2013-present)
  • Professor of Medicine, University of Chicago (2001–2013)
  • Director, University of Chicago Functional Genomics Facility (2000–2010)
  • Chief, Section of Nephrology, University of Chicago (1999–2009)
  • Associate Professor of Medicine, University of Chicago (1994–2001)
  • Assistant Professor Medicine, Medical College of Virginia (1988–1994)
  • Research Instructor in Medicine, Boston University School of Medicine (1987–1988)
See All (11 Total) >
Awards and Honors:
  • Fellow, American College of Physicians (2014)
  • Teacher of the Year, University of Chicago, Nephrology Section (2011)
  • Member, American Society for Clinical Investigation (2003)
  • Granted tenure (1999)
  • Falk Award of Excellence, Arthritis Foundation, Greater Chicago (1997)
  • XVth International Complement Workshop Travel Award, Kyoto, Japan (1993)
  • American Society of Nephrology Travel Award (1993)
  • XIVth International Complement Workshop Travel Award (1991)
  • First Independent Research Support Transition Award, NIH (1989)
  • American Society of Nephrology Travel Award (1987)
  • Individual National Research Service Award, NIH (1986)
  • Summa cum laude (1981)

Research Centers:
  • Clinical and Translational Research Center (CTRC)
  • Tissue targeted complement modulators Systemic suppression of the complement system has been shown to be effective to treat inflammatory disease, yet at the potential cost of compromising host defense and immune homeostasis. Herein disclosed are methods for antigen-specific targeting of complement inhibitors that show that complement inhibitors targeted to the proximal tubular epithelium protect against tubulointerstitial injury and renal dysfunction in a rat model of nephrosis. It is shown that appropriate targeting of a systemically administered complement inhibitor to a site of disease markedy enhances efficacy and obviates the need to systemically inhibit complement. Additionally, it is shown by specifically inhibiting the terminal pathway of complement, that the membrane attack complex (MAC) plays a key role in proteinuria-induced tubulointerstitial injury, thus establishing the MAC as a valid target for pharmacological intervention in proteinuric disorders. The disclosed are compositions can be used in methods of treating pathogenic diseases and inflammatory conditions by modulating the complement system. (2013)
  • Method for determining biological expression levels by linear programming (2006)

Evaluative Studies and Case Reports:
Journal Articles:
See All (103 Total) >

Professional Memberships:
  • American Medical Informatics Association (2012)
  • American Society for Clinical Investigation (2003)
  • American Society for Biochemistry and Molecular Biology (2002)
  • University of Chicago Cancer Research Center (2000)
  • American Heart Association, Council on the Kidney in Cardiovascular Disease (1993)
  • American Association of Immunologists (1992)
  • National Kidney Foundation (1990)
  • American Association for the Advancement of Science (1988)
  • American Society of Nephrology (1986)
  • International Society of Nephrology (1986)
  • International Society of Nephrology (1986)

Clinical Specialties:
Clinical Offices:
Insurance Accepted:

bottom-left cornerbottom-right corner

Contact Information

Clinical Translational Research Center
875 Ellicott Street, Suite 8030
Buffalo, NY 14203
Phone: 716-888-4826

Patient Care

Looking for a doctor? This faculty member is affiliated with UBMD, the group comprised of practicing physicians who are also professors in the UB School of Medicine and Biomedical Sciences.

View this faculty on UBMD

Log in to Update Your Profile